Tandem Diabetes Care Launches t:slim X2 Insulin Pump With Basal-IQ Technology

Tandem Diabetes Care Inc., manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring (CGM) integration, has launched the t:slim X2 Insulin Pump with Basal-IQ Technology, a predictive low glucose suspend (PLGS) feature designed to help reduce the frequency and duration of low glucose events (hypoglycemia). It is integrated with the Dexcom G6 CGM System, which requires no fingersticks for calibration or diabetes treatment decisions.^1,2 The company has begun sending emails with update instructions to all in-warranty t:slim X2 users in the United States, who have the option to add the new feature free of charge via remote software update.³
 
Tandem’s Basal-IQ algorithm is designed to look 30 minutes into the future to predict where glucose levels are heading. The device suspends insulin delivery when low glucose is predicted, then automatically resumes insulin delivery once glucose levels begin to rise. In the pivotal clinical study, use of the t:slim X2 Pump with Basal-IQ Technology demonstrated a 31 percent relative reduction in time spent below 70 mg/dL, with no rebound hyperglycemia compared to a CGM-enabled insulin pump without the feature. The system received high usability scores in the study, with 93 percent of participants indicating that the system was easy to use, and 97 percent indicating that they felt confident using the system.⁴
 
“This launch marks the achievement of our goal to offer people with diabetes a simple-to-use automated insulin delivery feature that can reduce time spent low without adding significant burden to the pump therapy experience,” said Kim Blickenstaff, president and CEO of Tandem Diabetes Care. “Our ability to provide remote software updates, allowing in-warranty t:slim X2 Pump users the ability to add Basal-IQ Technology to their current pumps using a personal computer, is unparalleled in the industry and further differentiates the t:slim X2 Insulin Pump from other devices on the market.”
 
Individual emails are being sent to all in-warranty t:slim X2 Pump users in the United States with information on how to start the update process. The Basal-IQ feature update will require a new prescription and completion of a 45-minute online training module, all of which will be coordinated through a simple-to-use online portal. Internet and computer access are required for pump updates. Basal-IQ Technology is only compatible with the Dexcom G6 CGM System. t:slim X2 Pump users who have Dexcom G5 Mobile CGM supplies they plan to use may want to postpone this update until they are ready to switch to the new Dexcom G6 CGM System.
 
Tandem’s free t:simulator App lets users experience the touchscreen interface of the t:slim X2 Insulin Pump with Basal-IQ Technology directly on a mobile device.

Tandem Diabetes Care Inc. designs, develops, and commercializes products for people with diabetes who use insulin. Tandem manufactures and sells the t:slim X2 Insulin Pump with Basal-IQ technology. The t:slim X2 Pump is capable of remote feature updates using a personal computer and is the only automated insulin delivery device approved for children as young as six years old. Tandem is based in San Diego, Calif.
 
Tandem Diabetes Care is a registered trademark, and t:slim X2, Basal-IQ and t:simulator are trademarks of Tandem Diabetes Care, Inc. Dexcom and Dexcom G6 are registered trademarks of Dexcom Inc.

References
1. If glucose alerts and CGM readings do not match symptoms or expectations or if taking over the recommended maximum dosage amount of 1000 mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions.
2. Dexcom G6 CGM sold separately. The Dexcom G6 CGM transmitter can only be paired with one medical device (either a Dexcom receiver or t:slim X2 Pump) and one consumer device (phone or tablet) at the same time.
3. A new prescription and additional training are required for this software update.
4. Forlenza GP, Li Z, Buckingham BA, Pinsker JE, et al. Predictive low glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: Results of the PROLOG trial [published online August 8, 2018]. Diabetes Care. doi:10.2337/dc18-0771.